{"title":"丙泊酚对小鼠血脑屏障完整性的急性影响","authors":"Ehsan Nozohouri, Yeseul Ahn, Sumaih Zoubi, Dhavalkumar Patel, Sabrina Rahman Archie, Khondker Ayesha Akter, Muhammad Bilal Siddique, Juyang Huang, Thomas J Abbruscato, Ulrich Bickel","doi":"10.1007/s11095-024-03735-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>We investigated whether short term infusion of propofol, a highly lipophilic agonist at GABA<sub>A</sub> receptors, which is in widespread clinical use as anesthetic and sedative, affects passive blood-brain barrier (BBB) permeability in vivo.</p><p><strong>Methods: </strong>Mice were anesthetized with an intraperitoneal injection of ketamine/xylazine followed by a continuous IV infusion of propofol in lipid emulsion through a tail vein catheter. Control groups received ketamine/xylazine anesthesia and an infusion of Intralipid, or ketamine/xylazine anesthesia only. [<sup>13</sup>C<sub>12</sub>]sucrose as a permeability marker was injected as IV bolus 15 min after start of the infusions. Brain uptake clearance, K<sub>in</sub>, of sucrose was calculated from the brain concentrations at 30 min and the area under the plasma-concentration time curve. We also measured the plasma and brain concentration of propofol at the terminal time point.</p><p><strong>Results: </strong>The K<sub>in</sub> value for propofol-infused mice was significantly higher, by a factor of 1.55 and 1.87, compared to the Intralipid infusion and the ketamine/xylazine groups, respectively, while the control groups were not significantly different. No difference was seen in the expression levels of tight junction proteins in brain across all groups. The propofol plasma concentration at the end of infusion (10.7 µM) matched the clinically relevant range of blood concentrations reported in humans, while concentration in brain was 2.5-fold higher than plasma.</p><p><strong>Conclusions: </strong>Propofol at clinical plasma concentrations acutely increases BBB permeability, extending our previous results with volatile anesthetics to a lipophilic injectable agent. This prompts further exploration, potentially refining clinical practices and ensuring safety, especially during extended propofol infusion schemes.</p>","PeriodicalId":20027,"journal":{"name":"Pharmaceutical Research","volume":" ","pages":"1599-1611"},"PeriodicalIF":3.5000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Acute Impact of Propofol on Blood-Brain Barrier Integrity in Mice.\",\"authors\":\"Ehsan Nozohouri, Yeseul Ahn, Sumaih Zoubi, Dhavalkumar Patel, Sabrina Rahman Archie, Khondker Ayesha Akter, Muhammad Bilal Siddique, Juyang Huang, Thomas J Abbruscato, Ulrich Bickel\",\"doi\":\"10.1007/s11095-024-03735-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>We investigated whether short term infusion of propofol, a highly lipophilic agonist at GABA<sub>A</sub> receptors, which is in widespread clinical use as anesthetic and sedative, affects passive blood-brain barrier (BBB) permeability in vivo.</p><p><strong>Methods: </strong>Mice were anesthetized with an intraperitoneal injection of ketamine/xylazine followed by a continuous IV infusion of propofol in lipid emulsion through a tail vein catheter. Control groups received ketamine/xylazine anesthesia and an infusion of Intralipid, or ketamine/xylazine anesthesia only. [<sup>13</sup>C<sub>12</sub>]sucrose as a permeability marker was injected as IV bolus 15 min after start of the infusions. Brain uptake clearance, K<sub>in</sub>, of sucrose was calculated from the brain concentrations at 30 min and the area under the plasma-concentration time curve. We also measured the plasma and brain concentration of propofol at the terminal time point.</p><p><strong>Results: </strong>The K<sub>in</sub> value for propofol-infused mice was significantly higher, by a factor of 1.55 and 1.87, compared to the Intralipid infusion and the ketamine/xylazine groups, respectively, while the control groups were not significantly different. No difference was seen in the expression levels of tight junction proteins in brain across all groups. The propofol plasma concentration at the end of infusion (10.7 µM) matched the clinically relevant range of blood concentrations reported in humans, while concentration in brain was 2.5-fold higher than plasma.</p><p><strong>Conclusions: </strong>Propofol at clinical plasma concentrations acutely increases BBB permeability, extending our previous results with volatile anesthetics to a lipophilic injectable agent. This prompts further exploration, potentially refining clinical practices and ensuring safety, especially during extended propofol infusion schemes.</p>\",\"PeriodicalId\":20027,\"journal\":{\"name\":\"Pharmaceutical Research\",\"volume\":\" \",\"pages\":\"1599-1611\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmaceutical Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11095-024-03735-w\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/7/24 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11095-024-03735-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/24 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
摘要
目的:我们研究了短期输注异丙酚是否会影响体内血脑屏障(BBB)的被动通透性:方法:给小鼠腹腔注射氯胺酮/恶嗪进行麻醉,然后通过尾静脉导管持续静脉注射丙泊酚脂质乳剂。对照组接受氯胺酮/恶嗪麻醉并输注 Intralipid,或仅接受氯胺酮/恶嗪麻醉。输注开始 15 分钟后,静脉注射[13C12]蔗糖作为渗透性标记物。蔗糖的脑吸收清除率 Kin 是根据 30 分钟时的脑浓度和血浆浓度时间曲线下的面积计算得出的。我们还测量了终点时间点丙泊酚的血浆和大脑浓度:结果:丙泊酚输注组和氯胺酮/恶嗪组的 Kin 值分别比 Intralipid 输注组和氯胺酮/恶嗪组高 1.55 倍和 1.87 倍,而对照组没有明显差异。各组脑内紧密连接蛋白的表达水平均无差异。输注结束时的丙泊酚血浆浓度(10.7 µM)符合人体血药浓度的临床相关范围,而大脑中的浓度是血浆浓度的2.5倍:结论:临床血浆浓度的丙泊酚会急性增加生物BB的通透性,这将我们之前对挥发性麻醉剂的研究结果扩展到了亲脂性注射剂。这促使我们进一步探索,从而有可能改进临床实践并确保安全,尤其是在延长异丙酚输注计划期间。
The Acute Impact of Propofol on Blood-Brain Barrier Integrity in Mice.
Purpose: We investigated whether short term infusion of propofol, a highly lipophilic agonist at GABAA receptors, which is in widespread clinical use as anesthetic and sedative, affects passive blood-brain barrier (BBB) permeability in vivo.
Methods: Mice were anesthetized with an intraperitoneal injection of ketamine/xylazine followed by a continuous IV infusion of propofol in lipid emulsion through a tail vein catheter. Control groups received ketamine/xylazine anesthesia and an infusion of Intralipid, or ketamine/xylazine anesthesia only. [13C12]sucrose as a permeability marker was injected as IV bolus 15 min after start of the infusions. Brain uptake clearance, Kin, of sucrose was calculated from the brain concentrations at 30 min and the area under the plasma-concentration time curve. We also measured the plasma and brain concentration of propofol at the terminal time point.
Results: The Kin value for propofol-infused mice was significantly higher, by a factor of 1.55 and 1.87, compared to the Intralipid infusion and the ketamine/xylazine groups, respectively, while the control groups were not significantly different. No difference was seen in the expression levels of tight junction proteins in brain across all groups. The propofol plasma concentration at the end of infusion (10.7 µM) matched the clinically relevant range of blood concentrations reported in humans, while concentration in brain was 2.5-fold higher than plasma.
Conclusions: Propofol at clinical plasma concentrations acutely increases BBB permeability, extending our previous results with volatile anesthetics to a lipophilic injectable agent. This prompts further exploration, potentially refining clinical practices and ensuring safety, especially during extended propofol infusion schemes.
期刊介绍:
Pharmaceutical Research, an official journal of the American Association of Pharmaceutical Scientists, is committed to publishing novel research that is mechanism-based, hypothesis-driven and addresses significant issues in drug discovery, development and regulation. Current areas of interest include, but are not limited to:
-(pre)formulation engineering and processing-
computational biopharmaceutics-
drug delivery and targeting-
molecular biopharmaceutics and drug disposition (including cellular and molecular pharmacology)-
pharmacokinetics, pharmacodynamics and pharmacogenetics.
Research may involve nonclinical and clinical studies, and utilize both in vitro and in vivo approaches. Studies on small drug molecules, pharmaceutical solid materials (including biomaterials, polymers and nanoparticles) biotechnology products (including genes, peptides, proteins and vaccines), and genetically engineered cells are welcome.